Imkeldi access in Lebanon: the MoPH-PDD named-patient pathway
How patients in the Lebanese Republic legally obtain Imkeldi (imatinib oral solution) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Lebanon access Imkeldi (imatinib oral solution) for chronic myeloid leukemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukemia in adult and pediatric patients through the MoPH-PDD named-patient pathway, a the Pharmacy and Drug Department of the Lebanese Ministry of Public Health-administered mechanism that allows a Lebanese-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in USD.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Lebanese patients need Imkeldi through the named-patient pathway
The Lebanese Republic operates a structured pharmaceutical regulatory environment. Imkeldi (imatinib oral solution) is regulated through MoPH-PDD (the Pharmacy and Drug Department of the Lebanese Ministry of Public Health) channels, and a Lebanese family asking for Imkeldi is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.
Four converging patterns drive these cases. First, indication lag. Imkeldi's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. out-of-pocket cash (fresh USD) payment, with limited NSSF (CNSS) coverage for chronic conditions and partial reimbursement under Bankers Assurance, MEDIS, and Allianz SNA private health plans each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Lebanon or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.
In each pattern, the MoPH-PDD named-patient pathway is the mechanism that connects a Lebanese-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Imkeldi is a BCR-ABL tyrosine kinase inhibitor in a ready-to-administer oral solution presentation, FDA-approved 2024 for patients who cannot swallow tablets, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.
Current regulatory status of Imkeldi in Lebanon
Imkeldi (imatinib mesylate oral solution; Shorla Oncology) is a ready-to-administer 80 mg/mL oral-solution formulation of imatinib, FDA-approved in 2024 for chronic myeloid leukaemia and Philadelphia-chromosome-positive acute lymphoblastic leukaemia in adult and paediatric patients - and specifically designed for patients who cannot swallow tablets (paediatric, geriatric, dysphagia). The active ingredient imatinib has been commercially available since 2001 as the tablet (Gleevec / Glivec); Imkeldi is a specific liquid presentation, not a new molecular entity.
Imatinib mesylate tablets are widely registered in Lebanon and broadly available as both originator (Gleevec / Glivec, Novartis) and generic. The Imkeldi oral solution presentation is, as of 2026-05-31, not publicly indexed on the MOPH registered drugs list. Lebanese patients requiring the liquid presentation (paediatric dosing not possible with tablet, swallowing difficulty in an adult patient) route through the MOPH Directorate of Pharmacy named-patient channel under Lebanese Pharmacy Profession Law No. 367/1994.
The file specifies the BCR-ABL1 cytogenetic and / or molecular diagnostic confirmation, disease phase (chronic / accelerated / blast crisis for CML, or new diagnosis / refractory for Ph+ ALL), the dysphagia justification or the paediatric indication, and the weight-banded dosing plan. Standard CML chronic-phase dosing is 400 mg / day for adults; paediatric dosing is 340 mg/m^2/day. The oral-solution allows precise weight-banded dosing without tablet crushing.
Last verified by ARCH-74: 2026-05-31.
Named tertiary centres in Lebanon where Imkeldi is dispensed
Imatinib for CML and Ph+ ALL is dispensed at haematology tertiary centres. Where the liquid presentation is requested, the dispensing centre is the same as for the tablet:
- American University of Beirut Medical Center (AUBMC), Beirut - Department of Adult Haematology, Department of Paediatric Haematology-Oncology at the Children's Cancer Center of Lebanon (CCCL).
- Children's Cancer Center of Lebanon (CCCL) at AUBMC, Beirut - principal paediatric haemato-oncology centre. Paediatric Imkeldi requests originate here. Source: CCCL.
- Hotel-Dieu de France de Beyrouth (USJ), Beirut - paediatric and adult haematology service.
- Saint George Hospital University Medical Center, Beirut - paediatric and adult haematology service.
- Mount Lebanon Hospital, Hazmieh - haematology service for the eastern Beirut corridor.
For adult patients with documented dysphagia (post-stroke, ALS, head-and-neck-cancer survivors) where the tablet is not acceptable, the request originates at the adult haematology clinic at AUBMC, Hotel-Dieu, or Saint George. The dispensing centre cross-checks the cytogenetic / molecular confirmation for CML or Ph+ ALL.
Local pricing reference for Imkeldi in Lebanon
US WAC reference for Imkeldi (imatinib mesylate oral solution 80 mg/mL) is in the order of USD 7,000 to USD 9,000 per 30-day supply at a typical adult 400 mg/day regimen (one 5 mL dose daily); per-mL pricing scales with strength. Source: Imkeldi FDA Prescribing Information.
Imatinib tablets (Gleevec / Glivec originator, plus multiple generics) are locally available in Lebanon at substantially lower prices in fresh USD; the cross-border Imkeldi route is meaningful only where the liquid presentation is clinically necessary. We quote Imkeldi-specific pricing only when the prescription explicitly specifies the oral solution; for standard tablet prescriptions we direct the prescriber to the locally available product.
Price snapshot date: 2026-05-31. Concomitant monitoring (CBC, hepatic, BCR-ABL transcript quantification at 3 / 6 / 12 / 18 months) is locally sourced and not part of the import file.
Country-specific access barriers for Imkeldi in Lebanon
The principal funding access for imatinib in Lebanon has historically been through the Glivec International Patient Assistance Program (GIPAP, administered by Novartis through The Max Foundation) for the tablet presentation. The GIPAP programme covers tablet-based therapy at no or substantially subsidised cost for eligible Lebanese patients; the programme does not customarily cover the Imkeldi specific oral-solution presentation because the cost-of-care is bundled with the standard tablet. Source: The Max Foundation.
Where the liquid presentation is clinically necessary, funding routes shift to self-pay in fresh USD, MOPH Pharmaceutical Aid Programme where eligibility is current (post-2019 fiscal-crisis constraints apply), or charitable channels through AUBMC / CCCL paediatric oncology fundraising. The dominant funding pattern is self-pay with charitable supplement.
Private-insurance coverage of an oral-solution imatinib presentation is policy-specific. NSSF (CNSS) coverage of the tablet for chronic CML is established through formulary inclusion; the oral solution as an unregistered named-patient product is typically not covered without advance pre-authorisation. For refugee Lebanese populations (Syrian, Palestinian) UNHCR / UNRWA-supported pathways cover oncology including CML at AUBMC and the public tertiary centres; named-patient imports of the liquid presentation are not customarily UNHCR-supplied.
The drug is ambient-storage; customs handling is routine. The liquid presentation requires room-temperature storage and has a specific shelf-life after opening; the dispensing pharmacy documents the storage chain. Each MOPH permit covers a defined supply window; chronic therapy requires permit renewal per cycle.
Recent local regulatory news touching Imkeldi or its drug class in Lebanon
No MOPH bulletin specifically naming the imatinib oral solution or the BCR-ABL tyrosine-kinase-inhibitor class has been observed in the last twelve months on the MOPH news and circulars page as of 2026-05-31. Adjacent context:
- FDA approval of Imkeldi (imatinib oral solution) in 2024 is the recent regulatory event for the drug; ongoing FDA labelling tracking for the broader imatinib class continues. Source: FDA Drugs@FDA database.
- Novartis Lebanon and The Max Foundation continue the GIPAP programme for the imatinib tablet; programme parameters update periodically. Source: The Max Foundation.
- MOPH continues iterative Pharmaceutical Aid Programme communications under post-crisis fiscal constraints. Source: MOPH.
What your physician needs to provide
For a Lebanese-licensed specialist prescribing Imkeldi through the MoPH-PDD pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for chronic myeloid leukemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukemia in adult and pediatric patients, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Imkeldi is the appropriate next step given a BCR-ABL tyrosine kinase inhibitor in a ready-to-administer oral solution presentation, FDA-approved 2024 for patients who cannot swallow tablets.
The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Imkeldi (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.
The treating physician's Lebanese license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.
Common questions about Imkeldi in Lebanon
Will out-of-pocket cash (fresh USD) payment, with limited NSSF (CNSS) coverage for chronic conditions and partial reimbursement under Bankers Assurance, MEDIS, and Allianz SNA private health plans cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Imkeldi is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is the FDA-approved indication recognised by MoPH-PDD? The MoPH-PDD named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; MoPH-PDD review focuses on the clinical justification rather than re-litigating the FDA decision.
My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Lebanese-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Lebanese Order of Physicians (Beirut or Tripoli branch) and the MoPH Pharmacy and Drug Department verifies the active license; the MoPH-PDD application records both the prescribing physician and the dispensing facility.
Can I receive Imkeldi at home? The dispensing facility must be Lebanese-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.
What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.
Where Reserve Meds fits in Imkeldi cases
Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace MoPH-PDD, and we do not replace your dispensing pharmacy. For Imkeldi specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Lebanon, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Imkeldi case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the MoPH-PDD application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Lebanese tertiary specialty care concentrates at AUBMC, Hotel-Dieu de France, LAU Medical Center-Rizk Hospital, Clemenceau Medical Center, and Mount Lebanon Hospital in Beirut and Hazmieh; following the post-2019 currency crisis, specialty-medicine pricing is quoted predominantly in fresh US dollars, and the MoPH Pharmacy and Drug Department named-patient import authorisation is the standard mechanism for unregistered specialty medicines.
Next step
If your Lebanese physician has prescribed Imkeldi and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.